Adding a GLP-1 drug after weight-loss surgery took off about five extra kilograms by six months. By a year the benefit was no longer statistically reliable, and every trial in the analysis tested the same drug: liraglutide, the oldest and weakest of the class.
That is the finding of a meta-analysis published June 23 ↗ in Acta Diabetologica, which pooled seven randomized controlled trials covering 460 patients. It is the first attempt to total up the evidence for a practice that has quietly become common. Bariatric surgery is the most effective obesity treatment there is. But a meaningful share of patients regain weight in the years after, and doctors increasingly add a GLP-1 drug to hold the line. Until now no one had checked whether that works.
What the pooled trials showed
At six months, patients who took a GLP-1 drug after surgery had lost about 5.3 kilograms more than those on placebo (a mean difference of 5.33 kg, 95 percent confidence interval 1.23 to 9.42). Measured as a share of body weight, the drug added about 5 percentage points of total weight loss (5.13 percent, confidence interval 2.14 to 8.11). Both results cleared statistical significance. Quality of life improved in the trials that measured it, and gastrointestinal side effects, the nausea and diarrhea the class is known for, were no more common than on placebo.
At twelve months the picture dissolved. The average extra weight loss was still around 5 kilograms, but the confidence interval ran from 22 kilograms of extra loss to 12 kilograms of extra gain. An interval that wide, straddling zero, means the pooled data can no longer tell a real effect from no effect at all. The reason is mundane: fewer of the seven trials reported a full year of follow-up, so the twelve-month estimate rests on thinner data than the six-month one. Blood sugar control, measured by HbA1c, did not differ from placebo at either timepoint, which is unsurprising in people whose diabetes had often already improved from the surgery itself.
The drug nobody reaches for first
The sharper signal is in the methods, not the results. All seven trials used liraglutide ↗, sold as Saxenda for weight and Victoza for diabetes. Liraglutide is a daily injection and the first GLP-1 drug to reach the weight-loss market. On its own it produces roughly 5 to 6 percent weight loss, a fraction of what the drugs that replaced it deliver.
Those replacements are semaglutide ↗ (Wegovy and Ozempic), which reaches about 15 percent, and tirzepatide ↗ (Zepbound and Mounjaro), which reaches around 20 percent. In a regular clinic, a patient regaining weight after surgery today is far more likely to be started on one of those weekly shots than on daily liraglutide. Yet the randomized evidence for the entire practice of adding a GLP-1 after surgery rests on the one drug that practice has largely moved past. The newer, stronger drugs are essentially untested in this specific setting in any randomized trial.
That gap matters because the two drugs are not interchangeable in degree. Say liraglutide buys five kilograms at six months. A drug two or three times more potent in head-to-head trials might buy more, or might meet the rerouted gut differently. Nobody has run the trial to say. The authors also flagged an exploratory finding: starting the drug early after surgery (within two months) versus late (after eighteen) seemed to change the response. That is another loose end for a properly powered study to settle.
All seven trials sit on the GLP-1 receptor ↗, the most heavily worked target on peptidemodel. The takeaway for someone weighing the option is narrow and honest: the early benefit is real, the durable benefit is unproven, and the modern drugs people actually use after surgery have yet to be tested the way the old one was. ↯